Evidence map›Paper›PMID 42429350›Full record

ArticleElectrophoresis2026

Glycosylation Signatures of Thyroglobulin in Papillary Thyroid Carcinoma.

Ali Hayatu, Esra Nur Akyildiz, Betul Karabudak, Sena Aksoy, Harun Erol, Bekir Salih, Hacı Mehmet Kayili

Abstract read
In one paragraph

Article in Electrophoresis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ali HayatuBiomedical Engineering Department, Faculty of Engineering and Natural Sciences, Karabük University, Karabük, Türkiye.
Esra Nur AkyildizBiomedical Engineering Department, Faculty of Engineering and Natural Sciences, Karabük University, Karabük, Türkiye.
Betul KarabudakBiomedical Engineering Department, Faculty of Engineering and Natural Sciences, Karabük University, Karabük, Türkiye.
Sena AksoyBiomedical Engineering Department, Faculty of Engineering and Natural Sciences, Karabük University, Karabük, Türkiye.
Harun ErolPathology Department, Faculty of Medicine, Karabük University, Karabük, Türkiye.
Bekir SalihChemistry Department, Faculty of Science, Hacettepe University, Ankara, Türkiye.
Hacı Mehmet KayiliBiomedical Engineering Department, Faculty of Engineering and Natural Sciences, Karabük University, Karabük, Türkiye.

Funding

Health Institutes of Türkiye 28731Presidency of the Republic of Turkey, Presidency of Strategy and Budget 2016 K121230
6 · The paper itself

Abstract

Thyroglobulin (Tg) is a clinically established biomarker for thyroid cancer; however, its diagnostic specificity remains limited due to confounding benign conditions. This study investigated changes in the site-specific N-glycosylation profiles of thyroglobulin protein derived from papillary thyroid cancer and adjacent healthy tissues. Using a bottom-up mass spectrometry-based glycoproteomic approach, we analyzed site-specific glycan compositions in retrospective patient tissue samples. Nine distinct N-glycosylation sites were identified and quantified in this study. Statistical analysis revealed significant differences in the site-specific glycosylation profiles. The glycan compositions HexNAc(3)Hex(5) and HexNAc(3)Hex(6) at the Asn1365 site exhibited a discriminatory potential. Dimensionality reduction and hierarchical clustering based on the top four glycopeptide variants showed observable grouping of tumor versus normal samples. Furthermore, supervised machine learning models were used to evaluate these features, with a neural network achieving the highest diagnostic performance (area under the curve [AUC] = 0.83). Feature importance analysis indicated that Asn1365-HexNAc(3)Hex(6) was the strongest contributor to the predictive power of the model. The observed alterations in specific glycan compositions, combined with machine learning evaluations, may offer improved diagnostic specificity and provide promising avenues for personalized thyroid cancer management.

Indexed as

CarcinomaThyroglobulinThyroid NeoplasmsBiomarkers, TumorCarcinoma, PapillaryGlycosylationHumansMass SpectrometryPolysaccharidesThyroid Cancer, PapillaryBiomarkers, TumorPolysaccharidesThyroglobulinmass spectrometryN‐glycosylationpapillary thyroid cancerthyroglobulin

Identifiers

PMID42429350
PMCPMC13572894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.